BeOne Medicines
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.
This study will enroll adults with solid tumors that cannot be removed by surgery or have spread to other parts of the body. BG-C477 is a targeted cancer medicine called an antibody-drug conjugate (ADC). An ADC consists of an antibody that is linked to a drug that can kill cancer cells. The antibody part of BG-C477 specifically attaches to a protein called CEA that is found on the surface of lung cancer cells. After it attaches to CEA, BG-C477 is taken inside the cancer cell where the drug (called topoisomerase I inhibitor) prevents the cell from multiplying and leads to cell death. The purp…
Inclusion Criteria: * Participants must sign the informed consent form (ICF) and be capable of giving written informed consent * Participants must consent to provide an archival tumor tissue sample or a fresh baseline biopsy * Phase 1a (Dose Escalation): Histologically confirmed advanced, metastatic, or unresectable solid tumors, that were previously treated with at least 2 lines of standard systemic therapy or for whom no standard treatment is available in the medical judgment of the investigator * Phase 1b (Dose Expansion) Part A: Histologically confirmed advanced or metastatic select solid…
Administered intravenously.
Administered intravenously.
Administered in accordance with relevant local guidelines and/or prescribing information.